With 2.99 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.3 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $10.715 whereas the lowest price it dropped to was $10.53. The 52-week range on BKD shows that it touched its highest point at $11.38 and its lowest point at $4.45 during that stretch. It currently has a 1-year price target of $10.95. BKD paid its most recent dividend on 1223424000, while the ex-dividend date for that was 1223424000. Beta for the stock currently stands at 0.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BKD was down-trending over the past week, with a drop of -4.32%, but this was up by 16.03% over a month. Three-month performance surged to 38.36% while six-month performance rose 58.81%. The stock gained 111.53% in the past year, while it has gained 90.68% so far this year. A look at the trailing 12-month EPS for BKD yields -1.31 with Next year EPS estimates of -0.47. For the next quarter, that number is -0.18. This implies an EPS growth rate of -26.74% for this year and 58.53% for next year. EPS is expected to grow by 26.74% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 9.24%.
Float and Shares Shorts:
At present, 237.53 million BKD shares are outstanding with a float of 214.12 million shares on hand for trading. On 2025-11-14, short shares totaled 13.52 million, which was 569.00002 higher than short shares on 1760486400. In addition to Ms. Dawn L. Kussow CPA as the firm’s Executive VP & CFO, Mr. Chad C. White serves as its Executive VP, General Counsel & Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, BKD reported revenue of $813165000.0 and operating income of $13202000.0. The EBITDA in the recently reported quarter was $111158000.0 and diluted EPS was -$0.48.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BKD since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BKD analysts setting a high price target of 14.0 and a low target of 6.75, the average target price over the next 12 months is 11.4375. Based on these targets, BKD could surge 31.58% to reach the target high and fall by -36.56% to reach the target low. Reaching the average price target will result in a growth of 7.5% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.69235 being high and -$0.73431 being low. For BKD, this leads to a yearly average estimate of -$0.71333. The surprise factor in the prior quarter was -$0.14. Based on analyst estimates, the high estimate for the next quarter is -$0.11 and the low estimate is -$0.11. The average estimate for the next quarter is thus -$0.11.
